Acute myeloid leukemia (AML) is a fast-moving blood cancer in which immature myeloid cells accumulate in the bone marrow and crowd out the normal cells needed to produce oxygen-carrying red blood cells, infection-fighting white blood cells and clot-forming platelets. For older adults and people unable to tolerate intensive chemotherapy, combinations built around the BCL-2 inhibitor venetoclax have transformed treatment. Yet the benefit is often temporary. Leukemic cells can adapt to venetoclax, while the immune environment surrounding them becomes increasingly hostile to effective immune surveillance. A new study published in Nature Cancer describes an experimental platform designed to confront both problems at once: it delivers venetoclax directly toward resistant leukemia cells while simultaneously redirecting natural killer cells against them.
The platform, named VINCENT, combines three therapeutic functions in a single strategy. Its antibody component recognizes CD16, a receptor found on natural killer, or NK, cells, and TIM3, an immune-regulatory protein expressed on a population of AML blasts and on dysfunctional immune cells. The third component is nanoformulated venetoclax, packaged in nanoscale carriers intended to improve delivery to the disease site and to cells bearing the target. By physically linking immune-cell engagement with drug delivery, the researchers sought to create a treatment that would not simply expose leukemia cells to more venetoclax, but would also bring activated NK cells into close contact with the malignant population. The approach is particularly relevant to AML cases in which conventional venetoclax-based regimens have stopped working.
Venetoclax normally promotes the death of vulnerable leukemia cells by inhibiting BCL-2, a protein that helps malignant cells resist programmed cell death. AML cells that acquire resistance may shift their dependence toward other members of the BCL-2 protein family, alter their mitochondrial metabolism or otherwise reduce the effectiveness of BCL-2 inhibition. Increasing the amount of free drug alone may therefore offer limited benefit and can increase systemic exposure. In VINCENT, nanoformulated venetoclax is incorporated into a targeted delivery system associated with antibodies against TIM3. The intended result is a higher local concentration of the drug within TIM3-positive malignant cells, where it can destabilize the leukemia cells’ survival machinery while antibody-mediated immune mechanisms add a second route to destruction.
The immune component of VINCENT relies on a mechanism known as antibody-dependent cellular cytotoxicity. When an antibody binds a target on a cancer cell through one arm and engages CD16 on an NK cell through another, it creates a molecular bridge between the immune effector and the malignant target. This connection can trigger NK-cell activation, release of cytotoxic granules and production of signals that promote target-cell death. The study reports that VINCENT increased NK-cell activity while eliminating TIM3-positive AML blasts. This is important because AML can suppress NK cells through chronic exposure to inhibitory signals, altered metabolic conditions and interactions with dysfunctional immune populations. Rather than treating NK cells as passive bystanders, the platform is designed to use them as active partners in the drug-delivery strategy.
In experiments involving venetoclax-resistant AML cell lines, VINCENT showed activity where venetoclax alone was inadequate. The researchers also tested the platform in patient-derived xenograft models, in which human AML cells are established in laboratory animals to preserve features of the disease in vivo. According to the study, VINCENT reduced resistant leukemia populations and extended its effects to TIM3-positive blasts and dysfunctional T cells. The removal of these cells may have broader consequences than direct tumor killing. TIM3-positive immune cells can contribute to an exhausted or suppressive microenvironment, and their depletion could help shift the leukemia niche toward conditions in which immune effector cells function more effectively. The findings remain preclinical, but they suggest that targeted delivery and immune redirection can be combined to address several layers of treatment failure.
The investigators next examined primary AML samples obtained from patients, a step that can reveal biological diversity often missed by experiments using standardized cell lines. In these samples, VINCENT selectively killed drug-resistant blasts, and its effectiveness varied according to the ratio between NK cells and TIM3-positive leukemia cells. Samples with a greater supply of NK cells relative to the targeted blast population tended to show stronger responses. This observation points toward a possible route for patient selection. A future clinical strategy might assess the abundance and functional state of NK cells alongside TIM3 expression before treatment, identifying patients whose immune-cell landscape is most compatible with the therapy. Such a biomarker would need to be validated prospectively, but the relationship provides an important clue about why some samples responded more strongly than others.
Single-cell transcriptomic analysis gave the researchers a higher-resolution view of the changes induced by VINCENT. This technology measures gene-expression patterns in individual cells, allowing malignant blasts and immune populations to be distinguished even when they occupy the same sample. The analysis indicated that VINCENT preferentially depleted blasts with high TIM3 expression and altered the surrounding immune ecosystem. Rather than leaving behind a uniformly suppressive environment, treatment appeared to remodel the leukemia-associated microenvironment toward a more immune-competent state. The reported changes included the loss of dysfunctional cellular populations and the restoration of gene-expression programs associated with immune activity. These molecular findings support the idea that VINCENT is not merely a targeted chemotherapy formulation but a coordinated intervention affecting both the cancer cells and the ecosystem that protects them.
TIM3 has attracted considerable interest as a target in AML because it is frequently detected on leukemic stem and progenitor populations as well as on exhausted immune cells. However, therapies that block TIM3 signaling have produced less impressive clinical results than initially hoped. One explanation is that blocking an inhibitory receptor does not necessarily eliminate the TIM3-positive cells that sustain disease or suppress immunity. VINCENT takes a different approach by using TIM3 as a docking site for drug delivery and immune-cell recruitment. This distinction may be critical: instead of relying solely on signal interruption, the platform attempts to remove the target population while simultaneously increasing the pressure exerted by NK cells. The study’s results suggest that a target associated with immune dysfunction can be converted into an entry point for a combined cytotoxic and immunological attack.
Despite the promise of the findings, VINCENT has not yet been established as a treatment for people with AML. The experiments described were performed in cell cultures, primary patient samples and patient-derived xenograft models, not in a completed human clinical trial. Important questions remain about manufacturing, pharmacokinetics, biodistribution, repeat dosing and potential toxicity. TIM3 is not exclusive to leukemia, and targeting it could affect normal immune regulation or other healthy cell populations. The balance between activating NK cells and provoking excessive inflammation will also require careful assessment. In addition, venetoclax resistance is biologically diverse, so not every resistant leukemia may depend on TIM3 or remain susceptible to improved drug delivery. Nevertheless, by combining targeted nanomedicine, antibody-dependent NK-cell engagement and microenvironmental remodeling, the study presents a technically integrated response to one of AML’s most difficult therapeutic problems. If the results can be reproduced in rigorous clinical studies, VINCENT could help establish a more personalized treatment model for older or medically unfit patients whose leukemia has progressed despite venetoclax-based therapy.
Subject of Research: Venetoclax-resistant acute myeloid leukemia and a TIM3-targeted, NK-cell-engaging therapeutic platform.
Article Title: TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.
Article References: Wang, Q., Li, J., Zeng, X. et al. “TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.” Nature Cancer (2026). https://doi.org/10.1038/s43018-026-01217-z
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s43018-026-01217-z
Keywords: Acute myeloid leukemia, AML, venetoclax resistance, TIM3, natural killer cells, NK-cell engager, nanoformulated drug delivery, immunotherapy, VINCENT, leukemia microenvironment.
Tags: AML targeted therapyDual-function immunotherapy and drug deliveryImmune environment and leukemia resistanceImmune modulation in AML therapyNanoformulated drug delivery systemsNatural killer cell engagement in blood cancerNK cell activation in leukemiaovercoming chemotherapy resistance in AMLTargeted nanomedicine for AML treatmentTIM3 and CD16 receptor targetingVenetoclax resistance in acute myeloid leukemiaVINCENT platform for AML treatment
